295 related articles for article (PubMed ID: 11818641)
1. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
[TBL] [Abstract][Full Text] [Related]
2. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
5. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study.
De Luca L; Sardella G; De Persio G; Petrolini A; Fedele F
Acute Card Care; 2008; 10(2):93-9. PubMed ID: 18568571
[TBL] [Abstract][Full Text] [Related]
6. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A
Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230
[TBL] [Abstract][Full Text] [Related]
7. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome.
Galassi AR; Russo G; Nicosia A; Tamburino C; Foti R; Rodi G; Calvi V; Gulizia G; Distefano G; Moshiri S; Giuffrida G
Cardiologia; 1999 Jul; 44(7):639-45. PubMed ID: 10476589
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.
Neumann FJ; Kastrati A; Schmitt C; Blasini R; Hadamitzky M; Mehilli J; Gawaz M; Schleef M; Seyfarth M; Dirschinger J; Schömig A
J Am Coll Cardiol; 2000 Mar; 35(4):915-21. PubMed ID: 10732888
[TBL] [Abstract][Full Text] [Related]
10. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
11. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
12. Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis.
Hong YJ; Jeong MH; Hwang SH; Yun NS; Lim SY; Lee SR; Hong SN; Kim KH; Park HW; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
Int J Cardiol; 2007 Dec; 123(1):23-8. PubMed ID: 17289173
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty.
Wijpkema JS; Jessurun GA; Van Boven AJ; Versteeg DI; Hautvast RW; Tio RA
Catheter Cardiovasc Interv; 2003 Nov; 60(3):339-43. PubMed ID: 14571484
[TBL] [Abstract][Full Text] [Related]
14. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting.
De Luca L; De Persio G; Minati M; Iacoboni C; Fedele F
Am Heart J; 2005 Jun; 149(6):1135. PubMed ID: 15976799
[TBL] [Abstract][Full Text] [Related]
15. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
PRICE Investigators
Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
[TBL] [Abstract][Full Text] [Related]
16. Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
Iijima R; Ndrepepa G; Mehilli J; Dirschinger J; Pache J; Seyfarth M; Schömig A; Kastrati A
Am J Cardiol; 2008 May; 101(9):1226-31. PubMed ID: 18435948
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
